A comprehensive view of Obesity. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

US Patent Issued to Regeneron Pharmaceuticals on March 26 for "Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)" (New York Inventors)

Amazon expects demand for anti-obesity drugs to boost pharma business; Amazon struck a deal earlier this month to dispense drugs on behalf of Zepbound maker Eli Lilly's direct-to-consumer service, LillyDirect

Amgen testing injectable weight loss drug MariTide that offers the potential of monthly administration; the drug appears promising in early trials in a market forecast to be worth up to US$100.0B by the end of the decade

Exposure to high levels of BPA could be linked to obesity and an altered gut microbiome, according to studies; researchers aim to further identify which specific microbes are involved in the connections between BPA, weight and the microbiome

Morningstar assigns Eli Lilly with US$500 fair value estimate, sees its competitive advantages lasting at least 20 years; with supply of Mounjaro/Zepbound expected to rise at least 50% in 2024, robust growth looks likely given capacity-constrained market

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count